Abdollahi A, Folkman J.:Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy Drug Resist Updat. Jan 8. [Epub ahead of print], 2010
Zabel-du Bois A, Wagner-Ecker M, Milker-Zabel S, Schwager C, Wirkner U, Debus J, Abdollahi A, Huber PE. :Gene Expression Signatures in the Peripheral Blood After Radiosurgery of Human Cerebral Arteriovenous Malformations. Strahlenther Onkol. Feb;186(2):91-98. Epub 2010 Jan 28, 2010
Behren A, Mühlen S, Acuna Sanhueza GA, Schwager C, Plinkert PK, Huber PE, Abdollahi A, Simon C. :Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion. Oncogene. Dec 21. [Epub ahead of print], 2009
Lee TY, Muschal S, Pravda EA, Folkman J, Abdollahi A, Javaherian K.:Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood. Aug 27;114(9):1987-98, 2009
comments in:
Mowery YM, Pizzo SV. The antitumorigenic trifecta. Blood. Aug 27;114(9):1727-8, 2009
Abiatari I, DeOliveira T, Kerkadze V, Schwager C, Esposito I, Giese NA, Huber P, Bergman F, Abdollahi A, Friess H, Kleeff J.:Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther. Jun;8(6):1494-504, 2009
Schwager C, Wirkner U, Abdollahi A, Huber PE.:TableButler - a Windows based tool for processing large data tables generated with high-throughput methods. BMC Bioinformatics. Jul 29;10:235, 2009
Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, Hlatky L, Vajkoczy P, Huber PE, Folkman J, Abdollahi A.:Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype. Cancer Research. 69:836-844, 2009
Domhan S, Muschal S, Schwager C, Morath C, Wirkner U, Ansorge W, Maercker C, Zeier M, Huber PE, Abdollahi A.:Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. Jun;7(6):1656-68, 2008
Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.:Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res. Apr 1;14(7):2210-9, 2008
Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, Hauser K, Hahnfeldt P, Hlatky L, Debus J, Peters JM, Friess H, Folkman J, Huber PE.:Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A Aug 16; Jul 31;104(31):12890-5. Epub 2007 Jul 24, 2007
Bedke J, Kiss E, Behnes CL, Popovic ZV, Heuser M, Stojanovic T, Sijmonsma T, Huber P, Domhan S, Muschal S, Abdollahi A, Gretz N, Grone HJ.:Anti-Inflammatory Effects of {alpha}v Integrin Antagonism in Acute Kidney Allograft Rejection. Am J Pathol. Aug 16; [Epub ahead of print], 2007
Abdollahi A, Hlatky L, Huber PE:
Endostatin: The logic of antiangiogenic therapy. Drug
Resist Updat 8: 59-74, 2005
Abdollahi A, Li M, Ping G, Plathow C, Domhan S,
Kiessling F, Lee LB, McMahon G, Gröne HJ, Lipson KE, Huber PE: Inhibition of platelet-derived growth
factor signaling attenuates pulmonary fibrosis. J Exp
Med 201: 925-35 2005
Huber PE, Bischof M, Heiland S, Peschke P,
Stoffregen C, Grone HJ, Debus J, Lipson K, Abdollahi
A: Trimodal cancer treatment: beneficial effects of
combined antiangiogenesis, radiation and chemotherapy. Cancer Res 65: 3643-55, 2005
Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson
KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA,
Debus J, Niethammer AG, Huber PE: Inhibition of
alpha(v)beta3 integrin survival signaling enhances
antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11: 6270-9, 2005
Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ,
Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE:
Endostatin´s antiangiogenic signaling network. Mol
Cell 13: 649-63, 2004
Abdollahi A, Lipson KE, Sckell A, Zieher H,
Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M,
Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE:
Combined therapy with Direct and indirect angiogenesis
inhibitors results in enhanced anti-angiogenic and
anti-tumor effects. Cancer Res 63:
8890-98, 2003
Abdollahi A, Lipson KE, Han X, Krempien R, Trinh
T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, Huber PE. SU5416 and SU6668 decrease angiogenic
effects of radiation-induced factor productions by tumor
cells and amplify the direct anti-endothelial action of
radiation in vitro. Cancer Res 63:
3755-63, 2003
|
a.amir(at)dkfz.de
